Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
July 21, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
xequelbio_digital.jpg
Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution
July 14, 2022 09:00 ET | Xequel Bio, Inc.
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...
Vaccentis appoints Martin Munte as CEO and strengthens Board
July 12, 2022 02:00 ET | Vaccentis AG
Martin Munte has extensive leadership experience at Amgen, AstraZeneca and RocheStrengthening management after appointment of three new Board members Zurich, Switzerland, July 12, 2022 -...
Vaccentis stärkt Management durch Berufung von Martin Munte zum CEO
July 12, 2022 02:00 ET | Vaccentis AG
Pharmamanager mit langjährige Führungserfahrung bei Amgen, AstraZeneca und RocheWeitere Verstärkung des Managements nach Ernennung dreier neuer Mitglieder im Verwaltungsrat Zurich, Schweiz, 12....
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
May 24, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
May 10, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...
Axim-Sapphire_Logo_-04 (1).png
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
April 27, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye...
Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Device, Expanded Patent Portfolio, and Further Clinical Studies
March 30, 2022 09:00 ET | Olympic Ophthalmics
ISSAQUAH, Wash., March 30, 2022 (GLOBE NEWSWIRE) -- Olympic Ophthalmics announced today that the U.S. Food and Drug Administration (FDA) has granted its 510(K) request for its second-generation...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
March 08, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
March 07, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...